Mesenchymal Stromal Cells for the Treatment of Non-union Fractures of Long Bones
Status:
Completed
Trial end date:
2019-12-20
Target enrollment:
Participant gender:
Summary
The present study evaluates the effect of XCEL-MT-OSTEO-ALPHA in non-union fractures
(pseudoarthrosis) of long bones in comparison to the standard treatment of autologous iliac
crest.
XCEL-MT-OSTEO-ALPHA is a tissue engineering product composed by "ex-vivo" expanded autologous
mesenchymal stromal cells fixed in allogenic bone tissue, produced by Xcelia (Blood and
Tissue Bank of Catalonia).
The working hypothesis proposes that the tissue engineering is a valid and useful technique
to achieve bone regeneration up to consolidation of non-union fractures.